STOCK TITAN

EQRx to Participate in the Jefferies 2022 London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST.

A live and archived webcast of the fireside chat will be available by visiting the News & Events section of EQRx’s website, and selecting Events & Presentations, at investors.eqrx.com.

About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and health systems. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRx_US LinkedIn, Instagram: @eqrxinc.

EQRx™ and Remaking Medicine™ are trademarks of EQRx.

EQRx Contacts:

Media:
Dan Budwick
1AB
dan@1abmedia.com

Investors:
investors@eqrx.com


EQRx, Inc.

NASDAQ:EQRX

EQRX Rankings

EQRX Latest News

EQRX Stock Data

1.14B
320.30M
11.14%
68.24%
2.04%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Cambridge

About EQRX

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States.